[Relationship between P-glycoprotein function in peripheral blood cells and multidrug resistance in breast carcinoma]. 2010

Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

OBJECTIVE To analyze the relationship between P-glycoprotein function in peripheral blood cells and primary multidrug resistance in breast carcinoma. METHODS P-gp function was investigated by flow cytometry in NK cells of 16 breast cancer patients treated with anthracyclines and taxanes. Among all the patients, 8 were in chemotherapy-sensitive group and 8 in chemotherapy-resistant group. P-gp function was determined by rhodamine 123 (Rh123)-ejection test. Mathematical model was established by a regression of the fluorescence-time curve. The efflux rate constants of the chemotherapy-sensitive and -resistant groups were compared. RESULTS There was no significant difference of Rh123 accumulation, retention or efflux between the two groups. The mathematical model of F(t) = F(0) ยท e(-kt) was established. K was the efflux rate constant, which was significantly different between the chemotherapy-sensitive and -resistant groups (P = 0.025). When k > 3.9 was used as diagnostic criterium for primary resistance, the sensitivity, specificity and accuracy were 75.0%, 100% and 87.5%, respectively. CONCLUSIONS P-glycoprotein function in peripheral blood cells is associated with primary multidrug resistance in breast carcinoma. The efflux rate constant may be a good predictor for chemotherapy sensitivity.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D043823 Taxoids A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS. Taxanes,Taxoid

Related Publications

Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
July 2011, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
December 1992, Surgery,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
December 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
December 1992, Blood,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
May 2004, Journal of medicinal chemistry,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
June 2012, Medical oncology (Northwood, London, England),
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
January 1991, Journal of the National Cancer Institute,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
January 1991, Patologia polska,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
May 1996, The New England journal of medicine,
Fei Ma, and Yu-qian Liao, and Ying Fan, and Ying-hong Wang, and Jian-ming Liang, and Jie Ma, and Bing-he Xu
May 1996, The New England journal of medicine,
Copied contents to your clipboard!